In a patient with a lumbar T-score of –2.2, high fracture risk, prior long‑term bisphosphonate use, adequate vitamin D, high osteoclast and low osteoblast activity, and eGFR > 35 mL/min, should teriparatide also be administered?

Should Teriparatide Be Administered in This Patient?

Yes, teriparatide is strongly indicated in this patient and should be initiated. This patient meets multiple criteria for anabolic therapy: high fracture risk, prior long-term bisphosphonate use with evidence of treatment failure (low osteoblast activity suggesting suppressed bone formation), and adequate renal function (eGFR >35 mL/min) 1, 2, 3.

Rationale for Teriparatide

High-Risk Profile Justifies Anabolic Therapy

This patient demonstrates:

• T-score of -2.2 with high fracture risk - While the T-score alone may not meet osteoporosis criteria, the designation of "high fracture risk" suggests additional clinical factors (likely prior fractures, age, or other risk factors) that warrant aggressive treatment
• Prior bisphosphonate failure - Long-term bisphosphonate use with persistently low osteoblast activity indicates the antiresorptive approach has maximally suppressed bone turnover without adequate bone formation
• Biochemical evidence of treatment failure - High osteoclast activity despite bisphosphonates suggests inadequate suppression, while low osteoblast activity indicates the need for anabolic stimulation

Evidence Supporting Teriparatide After Bisphosphonates

Teriparatide retains efficacy following bisphosphonate therapy, though the response may be somewhat blunted initially 1. The VERO trial subgroup analysis demonstrated similar fracture reductions in prior bisphosphonate users compared to treatment-naive patients, with vertebral and clinical fracture reductions of approximately 40% and 27-33% respectively 1. This is critical evidence that switching from bisphosphonates to anabolic therapy remains effective for fracture prevention.

The 2020 AACE/ACE guidelines explicitly state that teriparatide may be used in patients previously treated with bisphosphonates, acknowledging that BMD and bone turnover marker responses may be delayed but fracture efficacy is preserved 2.

Dosing and Administration

Administer teriparatide 20 mcg subcutaneously once daily 3:

• Inject into the thigh or abdominal region
• Initial doses should be given under circumstances where the patient can sit or lie down (risk of orthostatic hypotension)
• Continue supplemental calcium (up to 1500 mg total daily) and vitamin D (patient already has adequate vitamin D) 3
• Monitor serum calcium before initiation and after 1 month of treatment 2

Treatment Duration and Sequencing

Limit teriparatide to 2 years maximum 3. The FDA label explicitly states: "Use of teriparatide for more than 2 years during a patient's lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture" 3.

Critical: Sequential Therapy is Mandatory

After completing teriparatide, immediately transition to antiresorptive therapy 1, 2. This is non-negotiable because:

• Bone density declines rapidly within 1 year of stopping teriparatide if not followed by antiresorptive therapy 1, 2
• Bisphosphonates or denosumab after teriparatide maintain and may slightly enhance the anabolic gains 1
• There is no rationale for a washout period between stopping teriparatide and starting antiresorptive therapy 2

Options for sequential therapy include:

• Bisphosphonates (alendronate, risedronate, zoledronic acid)
• Denosumab
• Raloxifene (though less preferred for high-risk patients)

Renal Considerations

The patient's eGFR >35 mL/min makes teriparatide appropriate 3. Teriparatide does not require dose adjustment for renal function and is not contraindicated in moderate CKD. This is an advantage over bisphosphonates, which have restrictions at lower eGFR levels.

Monitoring Requirements

• Serum calcium: Check before starting and at 1 month 2, 3
• Bone turnover markers: Consider checking P1NP at 3-6 months to confirm anabolic response (baseline vitamin D status may influence early response) 4
• BMD: Repeat at 12-18 months to document response
• Orthostatic symptoms: Counsel patient about transient dizziness/hypotension with initial doses 3

Common Pitfalls to Avoid

1. Do not continue bisphosphonates concurrently with teriparatide - This blunts the anabolic effect 2, 5
2. Do not exceed 1500 mg total daily calcium - Risk of hypercalcemia 3, 5
3. Do not forget sequential antiresorptive therapy - Gains will be lost without it 1, 2
4. Do not use if patient has unexplained elevated alkaline phosphatase - Contraindication due to osteosarcoma concerns 2, 3

Contraindications to Verify

Ensure the patient does not have 3:

• Hypercalcemia or underlying hypercalcemic disorder
• Paget's disease of bone
• Prior skeletal radiation therapy
• Bone metastases or skeletal malignancies
• Open epiphyses (not applicable in this adult patient)
• Unexplained elevated alkaline phosphatase